Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for AbCellera Biologics (ABCL) through the VizualStocks API.
Active partner-led antibody programs in clinical development for which AbCellera retains potential milestone, royalty or other downstream economics. The count reflects programs AbCellera believes its partners are still progressing at the reporting date.
inTheClinicPartnerLedProgramsWithDownstreamsCumulative count under AbCellera's former KPI definition of unique antibody molecules that entered clinical development. A molecule qualified when an IND, New Animal Drug or equivalent application became open or otherwise approved.
legacyMoleculesInTheClinicCumulative count under AbCellera's former KPI definition of partner programs where antibody-discovery work had begun and AbCellera retained potential downstream economics. Discovery started after both the required reagents and the program kickoff were in place.
legacyPartnerInitiatedProgramStartsWithDownstreamsRevenue from transferring rights to AbCellera intellectual property and from royalties on partner or licensee sales. License fees are recognized when the customer can use the license; royalties are recognized as the underlying sales occur.
licensingAndRoyaltyRevenueRevenue earned when antibody-development partnerships achieve contractually specified research, development, regulatory or commercialization milestones. These payments are contingent and are not ordinary recurring research fees.
milestonePaymentsRevenueUnique antibody molecules with an open or approved IND, New Animal Drug or equivalent application for which AbCellera retains potential downstream economics. The count includes only molecules AbCellera believes partners are progressing toward approval at the reporting date.
moleculesInTheClinicWithDownstreamsActive partner-led antibody programs in discovery or preclinical development for which AbCellera retains potential milestone, royalty or other downstream economics. The count excludes programs already in clinical development.
preclinicalDevelopmentPartnerLedProgramsWithDownstreamsCumulative number of antibody-discovery programs covered by signed partner contracts under AbCellera's former KPI taxonomy. A contracted program did not necessarily mean discovery work had started or that a molecule had reached the clinic.
programsUnderContractRevenue from antibody-discovery research and related development services performed for AbCellera's partners. It is recognized as AbCellera satisfies the research obligations in each collaboration agreement.
researchFeesRevenueTotal active partner-led antibody programs for which AbCellera retains potential milestone, royalty or other downstream economics. It combines programs in discovery or preclinical development with those that have entered the clinic.
totalPartnerLedProgramsWithDownstreamsAbCellera revenue from research fees, milestone payments, and licensing and royalties. The mix can vary materially because milestones and royalties depend on partner progress and product sales rather than research activity alone.
totalRevenue